FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients

Nicola S Fracchiolla, Silvia Artuso, Agostino Cortelezzi, Anna M Pelizzari, Paola Tozzi, Maurizio Bonfichi, Federica Bocchio, Livio Gargantini, Elisa De Rosa, Giuseppe D Vighi, Lucia Prestini, Simona Sammassimo, Niccolò Frungillo, Maria C Pasquini, Alessandra Ragazzi, Daniele Boghi, Alessia Pastore, Eraldo Lanzi, Giuseppe Gritti, Giulia QuaresminiSimone Voltolini, Roberta Gaiardoni, Consuelo Corti, Maria C Vilardo, Maria L La Targia, Giacomo Berini, Massimo Magagnoli, Claudia Bacci, Dario Consonni, Alma L Rivolta, Giuliana Muti

Research output: Contribution to journalArticle

Abstract

Adverse drug reactions (ADRs) reduce patients' quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems. Nevertheless, the importance of ADR reporting is often underestimated. The project "FarmaREL" has been developed to monitor and evaluate ADRs in haematological patients and to increase pharmacovigilance culture among haematology specialists. In 13 haematology units, based in Lombardy, Italy, a dedicated specialist with the task of encouraging ADRs reporting and sensitizing healthcare professionals to pharmacovigilance has been assigned. The ADRs occurring in haematological patients were collected electronically and then analysed with multiple logistic regression. Between January 2009 and December 2011, 887 reports were collected. The number of ADRs was higher in older adults (528; 59%), in male (490; 55%), and in non-Hodgkin lymphoma patients (343; 39%). Most reactions were severe (45% required or prolonged hospitalization), but in most cases, they were fully resolved at the time of reporting. According to Schumock and Thornton criteria, a percentage of ADRs as high as 7% was found to be preventable versus 2% according to reporter opinion. Patients' haematological diagnosis, not age or gender, resulted to be the variable that most influenced ADR, in particular severity and outcome. The employment of personnel specifically dedicated to pharmacovigilance is a successful strategy to improve the number and quality of ADR reports. "FarmaREL", the first programme of active pharmacovigilance in oncohaematologic patients, significantly contributed to reach the WHO "Gold Standard" for pharmacovigilance in Lombardy, Italy.

Original languageEnglish
Pages (from-to)299-306
Number of pages8
JournalHematological Oncology
Volume36
Issue number1
DOIs
Publication statusPublished - Feb 2018

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients'. Together they form a unique fingerprint.

  • Cite this

    Fracchiolla, N. S., Artuso, S., Cortelezzi, A., Pelizzari, A. M., Tozzi, P., Bonfichi, M., Bocchio, F., Gargantini, L., De Rosa, E., Vighi, G. D., Prestini, L., Sammassimo, S., Frungillo, N., Pasquini, M. C., Ragazzi, A., Boghi, D., Pastore, A., Lanzi, E., Gritti, G., ... Muti, G. (2018). FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients. Hematological Oncology, 36(1), 299-306. https://doi.org/10.1002/hon.2451